Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States

Eghrari-Sabet, Jacqueline; Sher, Ellen; Kavati, Abhishek; Pilon, Dominic; Zhdanava, Maryia; Balp, Maria‐Magdalena; Lefèbvre, Patrick; Ortiz, Benjamin; Bernstein, Jonathan A.

doi:10.2500/aap.2018.39.4132

Cited by 14 publications

(12 citation statements)

References 22 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combined treatment lasted for 3 months without the occurrence of adverse events [19]. As in the cases mentioned previously, our patient required a very short course of treatment with omalizumab (6 months) compared with the average (the mean ± SD omalizumab treatment duration was 9.1 ± 3.8 months) [29]. One may speculate that the synergistic action of the two biological drugs in reducing systemic inflammation could be held responsible of the shorter time required to obtain clinical response.…”

Section: Discussionsupporting

confidence: 53%

Omalizumab and Adalimumab: A Winning Couple

et al. 2020

View full text Add to dashboard Cite

Introduction: We report a case of a young female patient, previously affected by psoriatic arthritis, and treated with adalimumab, who developed a chronic spontaneous urticaria and started a concomitant therapy with omalizumab. Methods & results: A 50% reduction of the Dermatology Life Quality Index (from 7 at baseline to 4 in weeks 12 and 24) and a complete reset of the Urticaria Activity Score for 7 days (from 27 at baseline to 0 in weeks 12 and 24) were recorded. During all treatment with omalizumab, administering of adalimumab was continued. Due to complete control of urticaria symptoms, the patient stopped treatment with omalizumab after 24 weeks. Conclusion: The combination of adalimumab and omalizumab could offer a favorable efficacy and safety profile. The synergistic action of the two biological drugs in reducing systemic inflammation could be responsible for a shorter time to obtain clinical response.

show abstract

Section: Discussionsupporting

confidence: 53%

Omalizumab and Adalimumab: A Winning Couple

et al. 2020

View full text Add to dashboard Cite

show abstract

“…RWE after approval of omalizumab demonstrated that symptoms recur in most patients after withdrawal of omalizumab and that re-starting is effective. 86 After withdrawal for ≥3 months, 21% of patients with a relapse of urticaria restarted omalizumab after a mean time ± SD of 4.4 ± 1.3 months. 86 The OPTIMA study (NCT02161562) has demonstrated that re-treatment with omalizumab 300 mg/q4w in patients with post-withdrawal relapse was not associated with reduced efficacy.…”

Section: Resultsmentioning

confidence: 98%

“… 86 After withdrawal for ≥3 months, 21% of patients with a relapse of urticaria restarted omalizumab after a mean time ± SD of 4.4 ± 1.3 months. 86 The OPTIMA study (NCT02161562) has demonstrated that re-treatment with omalizumab 300 mg/q4w in patients with post-withdrawal relapse was not associated with reduced efficacy. 87 Slow responders and non-responders were similar in terms of clinical and serological features, implicating that at least three injections of omalizumab should be tried.…”

Section: Resultsmentioning

confidence: 98%

Anti-IgE for the Treatment of Chronic Urticaria

Wedi

Traidl

2021

ITT

View full text Add to dashboard Cite

Urticaria and angioedema are very common. Management of chronic urticaria subtypes, which usually persist for many years, is challenging. Recent years have demonstrated that targeting IgE with antibodies provides a safe and efficient treatment approach. Whilst several anti-IgE antibodies have been developed, omalizumab is currently the only one approved for use. International and national guidelines recommend its use after failure of antihistamines at standard and increased dose. Whilst not yet approved, many new anti-IgE approaches are currently being investigated in pre-clinical studies or clinical trials. This non-systematic focused review summarizes current knowledge of omalizumab and other anti-IgE biologics in chronic urticaria using data extracted from PubMed, Google Scholar and clinical trial databases, clinicaltrials.gov and clinicaltrials.eu. For adults, there is good evidence from randomized clinical trials and real-world data that symptomatic treatment with omalizumab is efficacious and safe in chronic spontaneous urticaria (CSU), whereas evidence in chronic inducible urticaria (CINDU) and special populations is limited. Easy-to-use tools to identify non-responders and predict the required duration of treatment have not been established yet. Phase 2 b results of ligelizumab have not only demonstrated efficacy and safety but also superiority to omalizumab. Indeed, there is preliminary evidence that omalizumab non- or partial responders benefit from ligelizumab. Whereas further development of quilizumab was discontinued, other approaches, eg UB-221 or DARPins are under investigation. Anti-IgE treatment with omalizumab represents a landmark in the treatment of chronic urticaria, with and without angioedema, and there is light on the horizon suggesting success may come with various next-generation anti-IgE approaches.

show abstract

“…26 Chronic urticaria (CU) is another topic frequently addressed in previous issues of the Proceedings. [27][28][29][30][31][32][33][34][35][36] The urticaria control test (UCT) is a patient-reported outcome measure designed to determine the current level of disease control in patients with CU. Recently, a Brazilian UCT was developed, but its validity and reliability were unknown.…”

mentioning

confidence: 99%